Search research articles
Contact Us
Filters
Showing results (21-30 of 227) with videos related to
Page
of 23
Sort By:
Seminars in Oncology
|
August 27, 2013
Immune therapy for kidney cancer: a second dawn?
David F McDermott, Michael B Atkins
Hematology/Oncology Clinics of North America
|
June 2, 2014
Interferon, interleukin-2, and other cytokines
Elizabeth I Buchbinder, David F McDermott
Cancer Journal (Sudbury, Mass.)
|
October 7, 2008
Immunotherapy of metastatic renal cell carcinoma
David F McDermott, Michael B Atkins
Clinical Genitourinary Cancer
|
August 21, 2009
The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma
Jessica M Clement, David F McDermott
Nature Reviews. Urology
|
February 6, 2020
Checkpoint inhibitor immunotherapy in kidney cancer
Wenxin Xu, Michael B Atkins, David F McDermott
Cancer
|
May 9, 2025
The emerging role of lymphocyte-activation gene 3 targeting in the treatment of solid malignancies
Vinay K Giri, David F McDermott, Jacob Zaemes
Cancer Management and Research
|
December 29, 2010
Management of metastatic renal cell carcinoma in patients with poor prognosis
Andrea Bullock, David F McDermott, Michael B Atkins
The Oncologist
|
May 1, 2019
Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
Xin Gao, David F McDermott, M Dror Michaelson
Expert Review of Anticancer Therapy
|
June 14, 2022
Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval
Hollis Viray, David F McDermott, David J Einstein
Cancer Journal (Sudbury, Mass.)
|
January 24, 2017
Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era
Benjamin Izar, Meredith M Regan, David F McDermott
Page
of 23
Search research articles
Search
Showing results (21-30 of 227) with videos related to
Sort By:
Page
of 23
Seminars in Oncology
|
August 27, 2013
Immune therapy for kidney cancer: a second dawn?
David F McDermott, Michael B Atkins
Hematology/Oncology Clinics of North America
|
June 2, 2014
Interferon, interleukin-2, and other cytokines
Elizabeth I Buchbinder, David F McDermott
Cancer Journal (Sudbury, Mass.)
|
October 7, 2008
Immunotherapy of metastatic renal cell carcinoma
David F McDermott, Michael B Atkins
Clinical Genitourinary Cancer
|
August 21, 2009
The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma
Jessica M Clement, David F McDermott
Nature Reviews. Urology
|
February 6, 2020
Checkpoint inhibitor immunotherapy in kidney cancer
Wenxin Xu, Michael B Atkins, David F McDermott
Cancer
|
May 9, 2025
The emerging role of lymphocyte-activation gene 3 targeting in the treatment of solid malignancies
Vinay K Giri, David F McDermott, Jacob Zaemes
Cancer Management and Research
|
December 29, 2010
Management of metastatic renal cell carcinoma in patients with poor prognosis
Andrea Bullock, David F McDermott, Michael B Atkins
The Oncologist
|
May 1, 2019
Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
Xin Gao, David F McDermott, M Dror Michaelson
Expert Review of Anticancer Therapy
|
June 14, 2022
Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval
Hollis Viray, David F McDermott, David J Einstein
Cancer Journal (Sudbury, Mass.)
|
January 24, 2017
Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era
Benjamin Izar, Meredith M Regan, David F McDermott
Page
of 23